{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:09:33Z","timestamp":1793642973274,"version":"4.5.1"},"reference-count":336,"publisher":"Oxford University Press (OUP)","issue":"38","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016405","name":"European Atherosclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016405","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Obesity rates have surged since 1990 worldwide. This rise is paralleled by increases in pathological processes affecting organs such as the heart, liver, and kidneys, here termed systemic metabolic disorders (SMDs). For clinical management of SMD, the European Atherosclerosis Society proposes a pathophysiology-based system comprising three stages: Stage 1, where metabolic abnormalities such as dysfunctional adiposity and dyslipidaemia occur without detectable organ damage; Stage 2, which involves early organ damage manifested as Type 2 diabetes, asymptomatic diastolic dysfunction, metabolic-associated steatohepatitis (MASH), and chronic kidney disease (CKD); and Stage 3, characterized by more advanced organ damage affecting multiple organs. Various forms of high-risk obesity, driven by maintained positive energy balance, are the most common cause of SMD, leading to ectopic lipid accumulation and insulin resistance. This progression affects various organs, promoting comorbidities such as hypertension and atherogenic dyslipidaemia. Genetic factors influence SMD susceptibility, and ethnic disparities in SMD are attributable to genetic and socioeconomic factors. Key SMD features include insulin resistance, inflammation, pre-diabetes, Type 2 diabetes, MASH, hypertension, CKD, atherogenic dyslipidaemia, and heart failure. Management strategies involve lifestyle changes, pharmacotherapy, and metabolic surgery in severe cases, with emerging treatments focusing on genetic approaches. The staging system provides a structured approach to understanding and addressing the multi-faceted nature of SMD, which is crucial for improving health outcomes. Categorization of SMD abnormalities by presence and progression is aimed to improve awareness of a multi-system trait and encourage a tailored and global approach to treatment, ultimately aiming to reduce the burden of obesity-related comorbidities.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehaf314","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T06:28:57Z","timestamp":1745476137000},"page":"3685-3713","source":"Crossref","is-referenced-by-count":86,"title":["Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-4898","authenticated-orcid":false,"given":"Stefano","family":"Romeo","sequence":"first","affiliation":[{"name":"Department of Medicine , H7 Medicin, Huddinge, H7 Endokrinologi och Diabetes Romeo, Karolinska Institutet, 171 77 Stockholm ,","place":["Sweden"]},{"name":"Department of Endocrinology, Karolinska University Hospital Huddinge , 141 57 Huddinge, Stockholm ,","place":["Sweden"]},{"name":"Department of Molecular and Clinical Medicine\/Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Sahlgrenska University Hospital, 413 45 Gothenburg ,","place":["Sweden"]},{"name":"Department of Cardiology, Sahlgrenska University Hospital , 413 45 Gothenburg ,","place":["Sweden"]},{"name":"Clinical Nutrition Unit, Department of Medical and Surgical Sciences, University Magna Graecia , Viale Europa, 88100 Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vidal-Puig","sequence":"additional","affiliation":[{"name":"MRC Metabolic Diseases Unit, Institute of Metabolic Science, University of Cambridge , Addenbrooke's Hospital, Cambridge CB2 0QQ ,","place":["UK"]},{"name":"Centro de Investigacion Principe Felipe , C\/ d'Eduardo Primo Yufera, 3, 46012 Valencia ,","place":["Spain"]},{"name":"Cambridge University Nanjing Centre of Technology and Innovation , No. 23, Rongyue Road, Jiangbei New Area, Nanjing, Jiangsu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Husain","sequence":"additional","affiliation":[{"name":"Ted Rogers Centre for Heart Research, Department of Medicine, University of Toronto , 661 University Avenue, Toronto, ON , M5G 1M1","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rexford","family":"Ahima","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University School of Medicine , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome , Rome ,","place":["Italy"]},{"name":"Unit of Internal Medicine and Metabolic Diseases, Hospital Policlinico Umberto I , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Mae","family":"Diehl","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8500-5537","authenticated-orcid":false,"given":"Luigi","family":"Fontana","sequence":"additional","affiliation":[{"name":"Charles Perkins Centre, Faculty of Medicine and Health, University of Sydney , Camperdown, NSW ,","place":["Australia"]},{"name":"Department of Endocrinology, Royal Prince Alfred Hospital , Camperdown, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8079-4618","authenticated-orcid":false,"given":"Roger","family":"Foo","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, Yong Loo Lin School of Medicine, National University of Singapore, National University Health Systems ,","place":["Singapore"]},{"name":"Cardiovascular Metabolic Disease Translational Research Programme, National University Health Systems ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Fr\u00fchbeck","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Nutrition, Cl\u00ednica Universidad de Navarra, University of Navarra , Pamplona ,","place":["Spain"]},{"name":"Metabolic Research Laboratory, CIBER Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBEROBN), ISCIII , Pamplona ,","place":["Spain"]},{"name":"Obesity and Adipobiology Group, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdiSNA) , Pamplona ,","place":["Spain"]},{"name":"Metabolic Research Laboratory, Cl\u00ednica Universidad de Navarra , Pamplona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7720-2290","authenticated-orcid":false,"given":"Julia","family":"Kozlitina","sequence":"additional","affiliation":[{"name":"The Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]},{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]},{"name":"Peter O\u2019Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lonn","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University , Hamilton, ON ,","place":["Canada"]},{"name":"Population Health Research Institute, McMaster University and Hamilton Health Sciences , Hamilton, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Pattou","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Surgery, CHU Lille, University of Lille, Inserm, Institut Pasteur Lille , Lille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jogchum","family":"Plat","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Movement Sciences, NUTRIM School of Translational Research in Metabolism, Maastricht University , Maastricht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E","family":"Quaggin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]},{"name":"Division of Nephrology, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1249-4522","authenticated-orcid":false,"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Ryd\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Medicine (H7), Karolinska Institutet, Karolinska University Hospital Huddinge , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Segata","sequence":"additional","affiliation":[{"name":"Department CIBIO, University of Trento , Trento ,","place":["Italy"]},{"name":"Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Washington , Seattle, WA ,","place":["USA"]},{"name":"Providence Medical Research Center, Providence Inland Northwest Health , Spokane, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-8533","authenticated-orcid":false,"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael\u2019s Hospital, Unity Health Toronto, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-9962","authenticated-orcid":false,"given":"Jeanine","family":"Roeters van Lennep","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cardiovascular Institute, Erasmus Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1701-595X","authenticated-orcid":false,"given":"Marianne","family":"Benn","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital-Rigshospitalet, Centre of Diagnostic Investigation , Copenhagen ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-7050","authenticated-orcid":false,"given":"Christoph J","family":"Binder","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7139-4738","authenticated-orcid":false,"given":"Oveis","family":"Jamialahmadi","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine\/Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Sahlgrenska University Hospital, 413 45 Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2447-3286","authenticated-orcid":false,"given":"Rosie","family":"Perkins","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine\/Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Sahlgrenska University Hospital, 413 45 Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L","family":"Catapano","sequence":"additional","affiliation":[{"name":"Center for the Study of Atherosclerosis, IRCCS MultiMedica, Sesto S. Giovanni , Milan ,","place":["Italy"]},{"name":"Department of Pharmacological and Biomolecular Sciences, University of Milan , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hacettepe University Medical Faculty , Ankara ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0508-0954","authenticated-orcid":false,"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[{"name":"Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the European Atherosclerosis Society Consensus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph K","family":"Akyea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Kratky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margus","family":"Viigimaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belma","family":"Pojskic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phivos","family":"Symeonides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Vrablik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Reda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e4rt","family":"Elmet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Kaikkonen-M\u00e4\u00e4tt\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea","family":"Gamezardashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Weingartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sedding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralampos","family":"Milionis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christodoulos","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Paragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutaz","family":"Al-Khnifsawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaetaek","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkin","family":"Mirrakhimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Eduardo Garcia","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9 Parcero","family":"Vald\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Gaita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Rimbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Ezhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Guijarro","family":"Herr\u00e1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Gamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Guzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Mitchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"2025100619514158500_ehaf314-B1","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"Phelps","year":"2024","journal-title":"Lancet"},{"key":"2025100619514158500_ehaf314-B2","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","article-title":"A new framework for the diagnosis, staging and management of obesity in adults","volume":"30","author":"Busetto","year":"2024","journal-title":"Nat Med"},{"key":"2025100619514158500_ehaf314-B3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025100619514158500_ehaf314-B4","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B5","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00125-002-0873-y","article-title":"Adipose tissue as a buffer for daily lipid flux","volume":"45","author":"Frayn","year":"2002","journal-title":"Diabetologia"},{"key":"2025100619514158500_ehaf314-B6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/07853890500383895","article-title":"Is visceral obesity the cause of the metabolic syndrome?","volume":"38","author":"Despr\u00e9s","year":"2006","journal-title":"Ann Med"},{"key":"2025100619514158500_ehaf314-B7","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nature05488","article-title":"Abdominal obesity and metabolic syndrome","volume":"444","author":"Despr\u00e9s","year":"2006","journal-title":"Nature"},{"key":"2025100619514158500_ehaf314-B8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bbalip.2009.10.006","article-title":"Lipid homeostasis, lipotoxicity and the metabolic syndrome","volume":"1801","author":"Unger","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"2025100619514158500_ehaf314-B9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.bbalip.2009.12.006","article-title":"Adipose tissue expandability, lipotoxicity and the metabolic syndrome--an allostatic perspective","volume":"1801","author":"Virtue","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"2025100619514158500_ehaf314-B10","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1172\/JCI46043","article-title":"Circadian rhythms, sleep, and metabolism","volume":"121","author":"Huang","year":"2011","journal-title":"J Clin Invest"},{"key":"2025100619514158500_ehaf314-B11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-3-319-48382-5_7","article-title":"Adipose tissue function and expandability as determinants of lipotoxicity and the metabolic syndrome","volume":"960","author":"Carobbio","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"2025100619514158500_ehaf314-B12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1089\/met.2019.0115","article-title":"High-risk atherosclerosis and metabolic phenotype: the roles of ectopic adiposity, atherogenic dyslipidemia, and inflammation","volume":"18","author":"Lechner","year":"2020","journal-title":"Metab Syndr Relat Disord"},{"key":"2025100619514158500_ehaf314-B13","first-page":"15","article-title":"Genetic insights into cardiometabolic risk factors","volume":"35","author":"Whitfield","year":"2014","journal-title":"Clin Biochem Rev"},{"key":"2025100619514158500_ehaf314-B14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/ng.3285","article-title":"Meta-analysis of the heritability of human traits based on fifty years of twin studies","volume":"47","author":"Polderman","year":"2015","journal-title":"Nat Genet"},{"key":"2025100619514158500_ehaf314-B15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41576-021-00414-z","article-title":"The genetics of obesity: from discovery to biology","volume":"23","author":"Loos","year":"2022","journal-title":"Nat Rev Genet"},{"key":"2025100619514158500_ehaf314-B16","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/oby.23116","article-title":"Genetics of obesity: what we have learned over decades of research","volume":"29","author":"Bouchard","year":"2021","journal-title":"Obes Silver Spring Md"},{"key":"2025100619514158500_ehaf314-B17","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001077","article-title":"Polygenic risk scores for cardiovascular disease: a scientific statement from the American Heart Association","volume":"146","author":"O\u2019Sullivan","year":"2022","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B18","doi-asserted-by":"publisher","first-page":"D977","DOI":"10.1093\/nar\/gkac1010","article-title":"The NHGRI-EBI GWAS catalog: knowledgebase and deposition resource","volume":"51","author":"Sollis","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2025100619514158500_ehaf314-B19","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.2337\/db22-0478","article-title":"Disentangling genetic risks for metabolic syndrome","volume":"71","author":"van Walree","year":"2022","journal-title":"Diabetes"},{"key":"2025100619514158500_ehaf314-B20","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1038\/s41588-024-01933-1","article-title":"Multivariate genomic analysis of 5 million people elucidates the genetic architecture of shared components of the metabolic syndrome","volume":"56","author":"Park","year":"2024","journal-title":"Nat Genet"},{"key":"2025100619514158500_ehaf314-B21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2023.4115","article-title":"Mendelian randomization as a tool for cardiovascular research: a review","volume":"9","author":"Levin","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2025100619514158500_ehaf314-B22","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1093\/eurheartj\/ehad736","article-title":"Mendelian randomization for cardiovascular diseases: principles and applications","volume":"44","author":"Larsson","year":"2023","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B23","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1605086","article-title":"Genetic risk, adherence to a healthy lifestyle, and coronary disease","volume":"375","author":"Khera","year":"2016","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B24","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-019-0563-7","article-title":"Contribution of genetics to visceral adiposity and its relation to cardiovascular and metabolic disease","volume":"25","author":"Karlsson","year":"2019","journal-title":"Nat Med"},{"key":"2025100619514158500_ehaf314-B25","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1038\/s41467-022-30931-2","article-title":"Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots","volume":"13","author":"Agrawal","year":"2022","journal-title":"Nat Commun"},{"key":"2025100619514158500_ehaf314-B26","doi-asserted-by":"publisher","first-page":"117371","DOI":"10.1016\/j.atherosclerosis.2023.117371","article-title":"Disentangling the impact of gluteofemoral versus visceral fat accumulation on cardiometabolic health using sex-stratified Mendelian randomization","volume":"386","author":"Gagnon","year":"2023","journal-title":"Atherosclerosis"},{"key":"2025100619514158500_ehaf314-B27","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1001\/jama.2018.19329","article-title":"Association of genetic variants related to gluteofemoral vs abdominal fat distribution with type 2 diabetes, coronary disease, and cardiovascular risk factors","volume":"320","author":"Lotta","year":"2018","journal-title":"JAMA"},{"key":"2025100619514158500_ehaf314-B28","doi-asserted-by":"publisher","first-page":"e1002654","DOI":"10.1371\/journal.pmed.1002654","article-title":"Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis","volume":"15","author":"Udler","year":"2018","journal-title":"PLOS Med"},{"key":"2025100619514158500_ehaf314-B29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2337\/db18-0708","article-title":"Genome-wide and abdominal MRI data provide evidence that a genetically determined favorable adiposity phenotype is characterized by lower ectopic liver fat and lower risk of type 2 diabetes, heart disease, and hypertension","volume":"68","author":"Ji","year":"2019","journal-title":"Diabetes"},{"key":"2025100619514158500_ehaf314-B30","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2337\/db21-0129","article-title":"Genetic evidence for different adiposity phenotypes and their opposing influences on ectopic fat and risk of cardiometabolic disease","volume":"70","author":"Martin","year":"2021","journal-title":"Diabetes"},{"key":"2025100619514158500_ehaf314-B31","doi-asserted-by":"publisher","first-page":"e14531","DOI":"10.1111\/dme.14531","article-title":"Genetically defined favourable adiposity is not associated with a clinically meaningful difference in clinical course in people with type 2 diabetes but does associate with a favourable metabolic profile","volume":"38","author":"Heald","year":"2021","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"2025100619514158500_ehaf314-B32","doi-asserted-by":"publisher","first-page":"456","DOI":"10.2337\/diab.46.3.456","article-title":"Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women","volume":"46","author":"Albu","year":"1997","journal-title":"Diabetes"},{"key":"2025100619514158500_ehaf314-B33","doi-asserted-by":"publisher","first-page":"s302","DOI":"10.1007\/s00592-003-0093-z","article-title":"Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis","volume":"40","author":"Tanaka","year":"2003","journal-title":"Acta Diabetol"},{"key":"2025100619514158500_ehaf314-B34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ajcn\/86.2.353","article-title":"Visceral adipose tissue accumulation differs according to ethnic background: results of the multicultural community health assessment trial (M-CHAT)","volume":"86","author":"Lear","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"2025100619514158500_ehaf314-B35","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/ijo.2012.95","article-title":"Ethnic and sex differences in body fat and visceral and subcutaneous adiposity in children and adolescents","volume":"36","author":"Staiano","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"2025100619514158500_ehaf314-B36","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","article-title":"Obesity and cardiovascular disease: an ESC clinical consensus statement","volume":"45","author":"Koskinas","year":"2024","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B37","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/oby.23639","article-title":"Obesity among Asian American people in the United States: a review","volume":"31","author":"Li","year":"2023","journal-title":"Obesity"},{"key":"2025100619514158500_ehaf314-B38","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1161\/CIRCULATIONAHA.120.052430","article-title":"Quantifying and understanding the higher risk of atherosclerotic cardiovascular disease among South Asian individuals: results from the UK Biobank prospective cohort study","volume":"144","author":"Patel","year":"2021","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B39","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/hep.22726","article-title":"Ethnic differences in hepatic steatosis: an insulin resistance paradox?","volume":"49","author":"Guerrero","year":"2009","journal-title":"Hepatol Baltim Md"},{"key":"2025100619514158500_ehaf314-B40","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41569-024-01058-2","article-title":"Epidemiology of cardiometabolic health in Latin America and strategies to address disparities","volume":"21","author":"Brant","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2025100619514158500_ehaf314-B41","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.3390\/nu13072189","article-title":"Lifestyle factors and genetic variants associated to health disparities in the Hispanic population","volume":"13","author":"Fernandez","year":"2021","journal-title":"Nutrients"},{"key":"2025100619514158500_ehaf314-B42","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"2025100619514158500_ehaf314-B43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/BF00253736","article-title":"Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus","volume":"23","author":"DeFronzo","year":"1982","journal-title":"Diabetologia"},{"key":"2025100619514158500_ehaf314-B44","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"key":"2025100619514158500_ehaf314-B45","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2337\/dc05-2179","article-title":"Contributions of \u03b2-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose","volume":"29","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes Care"},{"key":"2025100619514158500_ehaf314-B46","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1210\/jc.2003-030087","article-title":"Insulin resistance\/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease","volume":"88","author":"Reaven","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100619514158500_ehaf314-B47","doi-asserted-by":"publisher","first-page":"F1087","DOI":"10.1152\/ajprenal.00340.2016","article-title":"Insulin resistance in chronic kidney disease: a systematic review","volume":"311","author":"Spoto","year":"2016","journal-title":"Am J Physiol-Ren Physiol"},{"key":"2025100619514158500_ehaf314-B48","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"2025100619514158500_ehaf314-B49","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jama.294.3.334","article-title":"Insulin resistance and risk of congestive heart failure","volume":"294","author":"Ingelsson","year":"2005","journal-title":"JAMA"},{"key":"2025100619514158500_ehaf314-B50","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2337\/diacare.25.7.1129","article-title":"Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes","volume":"25","author":"Hu","year":"2002","journal-title":"Diabetes Care"},{"key":"2025100619514158500_ehaf314-B51","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1161\/01.CIR.98.5.398","article-title":"Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki policemen study","volume":"98","author":"Py\u00f6r\u00e4l\u00e4","year":"1998","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B52","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nrendo.2015.216","article-title":"Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy","volume":"12","author":"Jia","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"2025100619514158500_ehaf314-B53","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/HYPERTENSIONAHA.120.16905","article-title":"Associations of insulin resistance with systolic and diastolic blood pressure: a study from the HCHS\/SOL","volume":"78","author":"Quesada","year":"2021","journal-title":"Hypertension"},{"key":"2025100619514158500_ehaf314-B54","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"2025100619514158500_ehaf314-B55","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2025100619514158500_ehaf314-B56","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.jhepr.2024.101092","article-title":"Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants","volume":"6","author":"Bril","year":"2024","journal-title":"JHEP Rep"},{"key":"2025100619514158500_ehaf314-B57","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1016\/j.cell.2024.06.029","article-title":"Diabetes mellitus\u2014progress and opportunities in the evolving epidemic","volume":"187","author":"Abel","year":"2024","journal-title":"Cell"},{"key":"2025100619514158500_ehaf314-B58","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"2025100619514158500_ehaf314-B59","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"2025100619514158500_ehaf314-B60","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/joim.12719","article-title":"Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver","volume":"283","author":"Dongiovanni","year":"2018","journal-title":"J Intern Med"},{"key":"2025100619514158500_ehaf314-B61","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J Hepatol"},{"key":"2025100619514158500_ehaf314-B62","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"2025100619514158500_ehaf314-B63","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/eurheartj\/ehx662","article-title":"Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals","volume":"39","author":"Lauridsen","year":"2018","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B64","doi-asserted-by":"publisher","first-page":"e029873","DOI":"10.1161\/JAHA.123.029873","article-title":"Serum metabolites are associated with HFpEF in biopsy-proven nonalcoholic fatty liver disease","volume":"12","author":"Wegermann","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2025100619514158500_ehaf314-B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2024.05.010","article-title":"Association of disproportionate liver fat with markers of heart failure: the multi-ethnic study of atherosclerosis","volume":"275","author":"Kusner","year":"2024","journal-title":"Am Heart J"},{"key":"2025100619514158500_ehaf314-B66","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jhep.2024.06.030","article-title":"Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer","volume":"81","author":"Ahmed","year":"2024","journal-title":"J Hepatol"},{"key":"2025100619514158500_ehaf314-B67","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","article-title":"Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Jamialahmadi","year":"2024","journal-title":"Nat Med"},{"key":"2025100619514158500_ehaf314-B68","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat Med"},{"key":"2025100619514158500_ehaf314-B69","doi-asserted-by":"publisher","first-page":"100479","DOI":"10.1016\/j.jhepr.2022.100479","article-title":"Lipid alterations in chronic liver disease and liver cancer","volume":"4","author":"Paul","year":"2022","journal-title":"JHEP Rep Innov Hepatol"},{"key":"2025100619514158500_ehaf314-B70","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/hep.21763","article-title":"A lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatology"},{"key":"2025100619514158500_ehaf314-B71","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1194\/jlr.P056002","article-title":"Biomarkers of NAFLD progression: a lipidomics approach to an epidemic","volume":"56","author":"Gorden","year":"2015","journal-title":"J Lipid Res"},{"key":"2025100619514158500_ehaf314-B72","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cmet.2015.06.007","article-title":"Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis","volume":"22","author":"Xia","year":"2015","journal-title":"Cell Metab"},{"key":"2025100619514158500_ehaf314-B73","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2337\/dc17-1318","article-title":"Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis","volume":"41","author":"Apostolopoulou","year":"2018","journal-title":"Diabetes Care"},{"key":"2025100619514158500_ehaf314-B74","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/978-3-319-48382-5_19","article-title":"Non-alcoholic fatty liver disease","volume":"960","author":"Engin","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"2025100619514158500_ehaf314-B75","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/cells8030277","article-title":"A new targeted lipidomics approach reveals lipid droplets in liver, muscle and heart as a repository for diacylglycerol and ceramide species in non-alcoholic fatty liver","volume":"8","author":"Preuss","year":"2019","journal-title":"Cells"},{"key":"2025100619514158500_ehaf314-B76","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1111\/liv.15059","article-title":"The role of hepatic lipid composition in obesity-related metabolic disease","volume":"41","author":"Willis","year":"2021","journal-title":"Liver Int"},{"key":"2025100619514158500_ehaf314-B77","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2025100619514158500_ehaf314-B78","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11892-021-01446-9","article-title":"Adipose tissue inflammation and cardiovascular disease: an update","volume":"22","author":"Rana","year":"2022","journal-title":"Curr Diab Rep"},{"key":"2025100619514158500_ehaf314-B79","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S2213-8587(19)30084-1","article-title":"Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement","volume":"7","author":"Neeland","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025100619514158500_ehaf314-B80","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41581-019-0145-4","article-title":"Obesity, kidney dysfunction and hypertension: mechanistic links","volume":"15","author":"Hall","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2025100619514158500_ehaf314-B81","doi-asserted-by":"publisher","first-page":"sfad282","DOI":"10.1093\/ckj\/sfad282","article-title":"Mechanisms and treatment of obesity-related hypertension\u2014part 1: mechanisms","volume":"17","author":"Parvanova","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025100619514158500_ehaf314-B82","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1161\/CIRCULATIONAHA.105.539528","article-title":"Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus","volume":"112","author":"Wilson","year":"2005","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B83","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1161\/HYPERTENSIONAHA.116.07876","article-title":"Regional fat distribution and blood pressure level and variability","volume":"68","author":"Yano","year":"2016","journal-title":"Hypertension"},{"key":"2025100619514158500_ehaf314-B84","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1053\/j.ajkd.2022.06.007","article-title":"Obstacles and opportunities in managing coexisting obesity and CKD: report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society","volume":"80","author":"Friedman","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2025100619514158500_ehaf314-B85","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/00041552-200411000-00006","article-title":"Atherosclerotic renal artery stenosis: current status and future directions","volume":"13","author":"Zalunardo","year":"2004","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025100619514158500_ehaf314-B86","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pcad.2021.03.003","article-title":"Renal artery stenosis","volume":"65","author":"Safian","year":"2021","journal-title":"Prog Cardiovasc Dis"},{"key":"2025100619514158500_ehaf314-B87","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1161\/HYPERTENSIONAHA.119.13419","article-title":"Nonalcoholic fatty liver disease","volume":"75","author":"Zhao","year":"2020","journal-title":"Hypertension"},{"key":"2025100619514158500_ehaf314-B88","doi-asserted-by":"publisher","first-page":"101238","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol Metab"},{"key":"2025100619514158500_ehaf314-B89","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00125-022-05765-8","article-title":"Intestinal lipid absorption and transport in type 2 diabetes","volume":"65","author":"Verg\u00e8s","year":"2022","journal-title":"Diabetologia"},{"key":"2025100619514158500_ehaf314-B90","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1210\/jcem.80.11.7593453","article-title":"Relationship between insulin-mediated glucose disposal by muscle and adipose tissue lipolysis in healthy volunteers","volume":"80","author":"Pei","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100619514158500_ehaf314-B91","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0026-0495(00)91065-5","article-title":"Insulin regulation of plasma free fatty acid concentrations is abnormal in healthy subjects with muscle insulin resistance","volume":"49","author":"Abbasi","year":"2000","journal-title":"Metabolism"},{"key":"2025100619514158500_ehaf314-B92","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1210\/edrv.23.2.0461","article-title":"Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes","volume":"23","author":"Lewis","year":"2002","journal-title":"Endocr Rev"},{"key":"2025100619514158500_ehaf314-B93","doi-asserted-by":"publisher","first-page":"771","DOI":"10.5551\/jat.RV17023","article-title":"Pathophysiology of diabetic dyslipidemia","volume":"25","author":"Hirano","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"2025100619514158500_ehaf314-B94","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1055\/s-2003-41284","article-title":"Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia","volume":"111","author":"Julius","year":"2003","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2025100619514158500_ehaf314-B95","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","article-title":"Diabetic dyslipidaemia: from basic research to clinical practice","volume":"46","author":"Taskinen","year":"2003","journal-title":"Diabetologia"},{"key":"2025100619514158500_ehaf314-B96","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B97","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study","volume":"44","author":"Bj\u00f6rnson","year":"2023","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B98","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/eurheartj\/ehac822","article-title":"Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality","volume":"44","author":"Wadstr\u00f6m","year":"2023","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B99","doi-asserted-by":"publisher","first-page":"e015801","DOI":"10.1161\/JAHA.119.015801","article-title":"Association of hypertriglyceridemia with all-cause mortality and atherosclerotic cardiovascular events in a low-risk Italian population: the TG-REAL retrospective cohort analysis","volume":"9","author":"Arca","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025100619514158500_ehaf314-B100","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1210\/clinem\/dgae371","article-title":"Machine learning reveals the contribution of lipoproteins to liver triglyceride content and inflammation","volume":"110","author":"Tavaglione","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100619514158500_ehaf314-B101","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"2025100619514158500_ehaf314-B102","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/MOL.0000000000000789","article-title":"ANGPTL3 as therapeutic target","volume":"32","author":"Kersten","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"2025100619514158500_ehaf314-B103","doi-asserted-by":"publisher","first-page":"100475","DOI":"10.1016\/j.jlr.2023.100475","article-title":"Apolipoprotein C3: form begets function","volume":"65","author":"Bornfeldt","year":"2024","journal-title":"J Lipid Res"},{"key":"2025100619514158500_ehaf314-B104","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3390\/ijms22020742","article-title":"The interplay between angiopoietin-like proteins and adipose tissue: another piece of the relationship between adiposopathy and cardiometabolic diseases?","volume":"22","author":"Bini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025100619514158500_ehaf314-B105","doi-asserted-by":"publisher","first-page":"154395","DOI":"10.1016\/j.metabol.2020.154395","article-title":"ApoCIII: a multifaceted protein in cardiometabolic disease","volume":"113","author":"D\u2019Erasmo","year":"2020","journal-title":"Metabolism"},{"key":"2025100619514158500_ehaf314-B106","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1093\/eurjpc\/zwaa152","article-title":"Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study","volume":"29","author":"Hussain","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2025100619514158500_ehaf314-B107","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1194\/jlr.P066183","article-title":"Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism","volume":"57","author":"Minicocci","year":"2016","journal-title":"J Lipid Res"},{"key":"2025100619514158500_ehaf314-B108","doi-asserted-by":"publisher","first-page":"e160607","DOI":"10.1172\/jci.insight.160607","article-title":"Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations","volume":"7","author":"Taskinen","year":"2022","journal-title":"JCI Insight"},{"key":"2025100619514158500_ehaf314-B109","doi-asserted-by":"publisher","first-page":"E493","DOI":"10.1152\/ajpendo.00195.2021","article-title":"Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8","volume":"321","author":"Sylvers-Davie","year":"2021","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2025100619514158500_ehaf314-B110","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1074\/jbc.M506519200","article-title":"The fasting-induced adipose factor\/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity","volume":"281","author":"Mandard","year":"2006","journal-title":"J Biol Chem"},{"key":"2025100619514158500_ehaf314-B111","doi-asserted-by":"publisher","first-page":"24013","DOI":"10.1038\/srep24013","article-title":"Association between betatrophin\/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"key":"2025100619514158500_ehaf314-B112","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1016\/j.numecd.2022.08.019","article-title":"Differential effects of bariatric surgery on plasma levels of ANGPTL3 and ANGPTL4","volume":"32","author":"Bini","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025100619514158500_ehaf314-B113","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/clinchem\/hvaa275","article-title":"Inflammation in atherosclerosis-no longer a theory","volume":"67","author":"Libby","year":"2021","journal-title":"Clin Chem"},{"key":"2025100619514158500_ehaf314-B114","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/01.ATV.21.6.961","article-title":"Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity","volume":"21","author":"Lemieux","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025100619514158500_ehaf314-B115","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"2025100619514158500_ehaf314-B116","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1194\/jlr.R066514","article-title":"Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment","volume":"57","author":"Ertunc","year":"2016","journal-title":"J Lipid Res"},{"key":"2025100619514158500_ehaf314-B117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI92035","article-title":"Inflammatory mechanisms linking obesity and metabolic disease","volume":"127","author":"Saltiel","year":"2017","journal-title":"J Clin Invest"},{"key":"2025100619514158500_ehaf314-B118","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.2337\/db06-1656","article-title":"Visceral fat adipokine secretion is associated with systemic inflammation in obese humans","volume":"56","author":"Fontana","year":"2007","journal-title":"Diabetes"},{"key":"2025100619514158500_ehaf314-B119","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s44161-024-00448-6","article-title":"Kupffer cells dictate hepatic responses to the atherogenic dyslipidemic insult","volume":"3","author":"Di Nunzio","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"2025100619514158500_ehaf314-B120","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s43587-024-00652-w","article-title":"Aging promotes metabolic dysfunction-associated steatotic liver disease by inducing ferroptotic stress","volume":"4","author":"Du","year":"2024","journal-title":"Nat Aging"},{"key":"2025100619514158500_ehaf314-B121","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/jama.286.3.327","article-title":"C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus","volume":"286","author":"Pradhan","year":"2001","journal-title":"JAMA"},{"key":"2025100619514158500_ehaf314-B122","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1161\/01.cir.0000055014.62083.05","article-title":"C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B123","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis","volume":"379","author":"Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium","year":"2012","journal-title":"Lancet Lond Engl"},{"key":"2025100619514158500_ehaf314-B124","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B125","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"2025100619514158500_ehaf314-B126","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41569-024-01045-7","article-title":"Autoimmune diseases and atherosclerotic cardiovascular disease","volume":"21","author":"Porsch","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2025100619514158500_ehaf314-B127","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCHEARTFAILURE.112.972828","article-title":"Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction","volume":"6","author":"Ho","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2025100619514158500_ehaf314-B128","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/eurheartj\/eht066","article-title":"Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND","volume":"34","author":"Brouwers","year":"2013","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B129","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacc.2016.11.081","article-title":"Relationship between physical activity, body mass index, and risk of heart failure","volume":"69","author":"Pandey","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025100619514158500_ehaf314-B130","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jchf.2018.07.009","article-title":"Adiposity and incident heart failure and its subtypes","volume":"6","author":"Rao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2025100619514158500_ehaf314-B131","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025100619514158500_ehaf314-B132","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025100619514158500_ehaf314-B133","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2025100619514158500_ehaf314-B134","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B135","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.1152\/ajpendo.00179.2022","article-title":"Obesity and chronic kidney disease","volume":"324","author":"Jiang","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2025100619514158500_ehaf314-B136","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.ackd.2012.12.006","article-title":"Direct and indirect effects of obesity on the kidney","volume":"20","author":"Alicic","year":"2013","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025100619514158500_ehaf314-B137","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12933-024-02399-5","article-title":"Epicardial and liver fat implications in albuminuria: a retrospective study","volume":"23","author":"Perdomo","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2025100619514158500_ehaf314-B138","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1093\/cvr\/cvab357","article-title":"Contributions of obesity to kidney health and disease: insights from Mendelian randomization and the human kidney transcriptomics","volume":"118","author":"Xu","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2025100619514158500_ehaf314-B139","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int"},{"key":"2025100619514158500_ehaf314-B140","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","article-title":"Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy","volume":"43","author":"Ridker","year":"2022","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B141","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41581-022-00621-9","article-title":"Targeting innate immunity-driven inflammation in CKD and cardiovascular disease","volume":"18","author":"Speer","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2025100619514158500_ehaf314-B142","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B143","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B144","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1161\/CIRCRESAHA.121.318093","article-title":"Obesity, adipose tissue and vascular dysfunction","volume":"128","author":"Koenen","year":"2021","journal-title":"Circ Res"},{"key":"2025100619514158500_ehaf314-B145","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/j.ackd.2014.03.003","article-title":"Cardiovascular complications of diabetic kidney disease","volume":"21","author":"P\u00e1lsson","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025100619514158500_ehaf314-B146","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jchf.2020.09.006","article-title":"Worsening kidney function is the major mechanism of heart failure in hypertension","volume":"9","author":"Khayyat-Kholghi","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2025100619514158500_ehaf314-B147","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2025100619514158500_ehaf314-B148","doi-asserted-by":"publisher","first-page":"E214","DOI":"10.1152\/ajpendo.1979.237.3.E214","article-title":"Glucose clamp technique: a method for quantifying insulin secretion and resistance","volume":"237","author":"DeFronzo","year":"1979","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2025100619514158500_ehaf314-B149","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"2025100619514158500_ehaf314-B150","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2337\/diabetes.47.10.1643","article-title":"Prevalence of insulin resistance in metabolic disorders: the Bruneck study","volume":"47","author":"Bonora","year":"1998","journal-title":"Diabetes"},{"key":"2025100619514158500_ehaf314-B151","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/met.2008.0034","article-title":"The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects","volume":"6","author":"Simental-Mend\u00eda","year":"2008","journal-title":"Metab Syndr Relat Disord"},{"key":"2025100619514158500_ehaf314-B152","doi-asserted-by":"publisher","first-page":"802","DOI":"10.7326\/0003-4819-139-10-200311180-00007","article-title":"Use of metabolic markers to identify overweight individuals who are insulin resistant","volume":"139","author":"McLaughlin","year":"2003","journal-title":"Ann Intern Med"},{"key":"2025100619514158500_ehaf314-B153","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12933-023-01762-2","article-title":"Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data","volume":"22","author":"Che","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2025100619514158500_ehaf314-B154","author":"World Health Organization"},{"key":"2025100619514158500_ehaf314-B155","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2337\/diaclin.33.2.97","article-title":"Standards of medical care in diabetes\u20142015 abridged for primary care providers","volume":"33","author":"American Diabetes Association","year":"2015","journal-title":"Clin Diabetes"},{"key":"2025100619514158500_ehaf314-B156","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/ijo.2011.100","article-title":"Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity","volume":"36","author":"G\u00f3mez-Ambrosi","year":"2012","journal-title":"Int J Obes"},{"key":"2025100619514158500_ehaf314-B157","doi-asserted-by":"publisher","first-page":"e14218","DOI":"10.1111\/eci.14218","article-title":"Revisiting the beyond BMI paradigm in excess weight diagnosis and management: a call to action","volume":"54","author":"Aguas-Ayesa","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"2025100619514158500_ehaf314-B158","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.mayocp.2013.11.011","article-title":"A pooled analysis of waist circumference and mortality in 650,000 adults","volume":"89","author":"Cerhan","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"2025100619514158500_ehaf314-B159","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1467-789X.2011.00952.x","article-title":"Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis","volume":"13","author":"Ashwell","year":"2012","journal-title":"Obes Rev"},{"key":"2025100619514158500_ehaf314-B160","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"2025100619514158500_ehaf314-B161","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.cgh.2022.03.044","article-title":"Development and validation of a score for fibrotic nonalcoholic steatohepatitis","volume":"21","author":"Tavaglione","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100619514158500_ehaf314-B162","doi-asserted-by":"publisher","first-page":"155790","DOI":"10.1016\/j.metabol.2024.155790","article-title":"Performance of non-invasive tests for liver fibrosis and resolution after bariatric surgery","volume":"153","author":"Raverdy","year":"2024","journal-title":"Metabolism"},{"key":"2025100619514158500_ehaf314-B163","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2025100619514158500_ehaf314-B164","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B165","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2025100619514158500_ehaf314-B166","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among apoB, non\u2013high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention","volume":"45","author":"Sniderman","year":"2024","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B167","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.124.068885","article-title":"Apolipoprotein B: bridging the gap between evidence and clinical practice","volume":"150","author":"De Oliveira-Gomes","year":"2024","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B168","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B169","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/s0195-668x(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B170","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 Working Group and ESC Cardiovascular Risk Collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B171","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jacc.2015.12.056","article-title":"Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium: the AWHS study","volume":"67","author":"Laclaustra","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025100619514158500_ehaf314-B172","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jacc.2017.05.033","article-title":"Subclinical atherosclerosis burden by 3D ultrasound in mid-life","volume":"70","author":"L\u00f3pez-Melgar","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025100619514158500_ehaf314-B173","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B174","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jacl.2020.12.005","article-title":"The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction","volume":"15","author":"Orringer","year":"2021","journal-title":"J Clin Lipidol"},{"key":"2025100619514158500_ehaf314-B175","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","article-title":"Universal definition and classification of heart failure","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"2025100619514158500_ehaf314-B176","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B177","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025100619514158500_ehaf314-B178","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2025100619514158500_ehaf314-B179","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B180","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jchf.2023.03.011","article-title":"How to manage heart failure with preserved ejection fraction: practical guidance for clinicians","volume":"11","author":"Desai","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2025100619514158500_ehaf314-B181","doi-asserted-by":"publisher","first-page":"e018689","DOI":"10.1161\/JAHA.120.018689","article-title":"Obesity and serial NT-proBNP levels in guided medical therapy for heart failure with reduced ejection fraction: insights from the GUIDE-IT trial","volume":"10","author":"Parcha","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025100619514158500_ehaf314-B182","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1253\/circj.CJ-20-1104","article-title":"Effects of age, sex, and obesity on N-terminal pro B-type natriuretic peptide concentrations in the general population","volume":"85","author":"Choi","year":"2021","journal-title":"Circ J Off J Jpn Circ Soc"},{"key":"2025100619514158500_ehaf314-B183","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"2025100619514158500_ehaf314-B184","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"2025100619514158500_ehaf314-B185","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1161\/CIR.0000000000001031","article-title":"2021 Dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association","volume":"144","author":"Lichtenstein","year":"2021","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B186","doi-asserted-by":"publisher","first-page":"e077310","DOI":"10.1136\/bmj-2023-077310","article-title":"Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses","volume":"384","author":"Lane","year":"2024","journal-title":"BMJ"},{"key":"2025100619514158500_ehaf314-B187","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41580-021-00411-4","article-title":"Molecular mechanisms of dietary restriction promoting health and longevity","volume":"23","author":"Green","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025100619514158500_ehaf314-B188","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S2213-8587(19)30151-2","article-title":"2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial","volume":"7","author":"Kraus","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025100619514158500_ehaf314-B189","doi-asserted-by":"publisher","first-page":"e12719","DOI":"10.1111\/acel.12719","article-title":"Effects of 2 years of caloric restriction on oxidative status assessed by urinary F2-isoprostanes: the CALERIE 2 randomized clinical trial","volume":"17","author":"Il\u2019yasova","year":"2018","journal-title":"Aging Cell"},{"key":"2025100619514158500_ehaf314-B190","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.18632\/aging.100994","article-title":"Long-term moderate calorie restriction inhibits inflammation without impairing cell-mediated immunity: a randomized controlled trial in non-obese humans","volume":"8","author":"Meydani","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"2025100619514158500_ehaf314-B191","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2337\/db16-0607","article-title":"Renal and systemic effects of calorie restriction in patients with type 2 diabetes with abdominal obesity: a randomized controlled trial","volume":"66","author":"Ruggenenti","year":"2017","journal-title":"Diabetes"},{"key":"2025100619514158500_ehaf314-B192","doi-asserted-by":"publisher","first-page":"E197","DOI":"10.1152\/ajpendo.00102.2007","article-title":"Calorie restriction or exercise: effects on coronary heart disease risk factors. A randomized, controlled trial","volume":"293","author":"Fontana","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2025100619514158500_ehaf314-B193","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2337\/dc18-0836","article-title":"Effect of a lifestyle intervention program with energy-restricted Mediterranean diet and exercise on weight loss and cardiovascular risk factors: one-year results of the PREDIMED-plus trial","volume":"42","author":"Salas-Salvad\u00f3","year":"2019","journal-title":"Diabetes Care"},{"key":"2025100619514158500_ehaf314-B194","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/joim.20038","article-title":"Effect of an intensive lifestyle intervention on cystatin C\u2013based kidney function in adults with overweight and obesity: from the PREDIMED-Plus trial","volume":"297","author":"Mart\u00ednez-Montoro","year":"2025","journal-title":"J Intern Med"},{"key":"2025100619514158500_ehaf314-B195","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial","volume":"7","author":"Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025100619514158500_ehaf314-B196","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"2025100619514158500_ehaf314-B197","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.advnut.2023.10.003","article-title":"Effects of intermittent energy restriction compared with those of continuous energy restriction on body composition and cardiometabolic risk markers\u2014a systematic review and meta-analysis of randomized controlled trials in adults","volume":"15","author":"Schroor","year":"2024","journal-title":"Adv Nutr"},{"key":"2025100619514158500_ehaf314-B198","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.celrep.2016.09.047","article-title":"High-protein intake during weight loss therapy eliminates the weight-loss-induced improvement in insulin action in obese postmenopausal women","volume":"17","author":"Smith","year":"2016","journal-title":"Cell Rep"},{"key":"2025100619514158500_ehaf314-B199","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/gerona\/glx227","article-title":"Health benefits of the Mediterranean diet: metabolic and molecular mechanisms","volume":"73","author":"Tosti","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2025100619514158500_ehaf314-B200","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1093\/eurheartj\/ehad436","article-title":"Vegetarian and vegan diets: benefits and drawbacks","volume":"44","author":"Wang","year":"2023","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B201","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jama.2019.14120","article-title":"Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease","volume":"322","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"2025100619514158500_ehaf314-B202","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pcad.2018.05.004","article-title":"Portfolio dietary pattern and cardiovascular disease: a systematic review and meta-analysis of controlled trials","volume":"61","author":"Chiavaroli","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"2025100619514158500_ehaf314-B203","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ajcnut.2023.03.018","article-title":"Effect of calorie restriction in comparison to usual diet or usual care on remission of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"117","author":"Jayedi","year":"2023","journal-title":"Am J Clin Nutr"},{"key":"2025100619514158500_ehaf314-B204","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00592-020-01568-8","article-title":"Low-carbohydrate diets and type 2 diabetes treatment: a meta-analysis of randomized controlled trials","volume":"57","author":"Silverii","year":"2020","journal-title":"Acta Diabetol"},{"key":"2025100619514158500_ehaf314-B205","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/ajcn\/87.1.114","article-title":"The Canadian trial of carbohydrates in diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein","volume":"87","author":"Wolever","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"2025100619514158500_ehaf314-B206","doi-asserted-by":"publisher","first-page":"n1651","DOI":"10.1136\/bmj.n1651","article-title":"Effect of low glycaemic index or load dietary patterns on glycaemic control and cardiometabolic risk factors in diabetes: systematic review and meta-analysis of randomised controlled trials","volume":"374","author":"Chiavaroli","year":"2021","journal-title":"BMJ"},{"key":"2025100619514158500_ehaf314-B207","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.2337\/dc10-9990","article-title":"Exercise and type 2 diabetes","volume":"33","author":"Colberg","year":"2010","journal-title":"Diabetes Care"},{"key":"2025100619514158500_ehaf314-B208","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/ajcn\/84.5.1033","article-title":"Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial","volume":"84","author":"Weiss","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"2025100619514158500_ehaf314-B209","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1089\/rej.2007.0622","article-title":"Caloric restriction but not exercise-induced reductions in fat mass decrease plasma triiodothyronine concentrations: a randomized controlled trial","volume":"11","author":"Weiss","year":"2008","journal-title":"Rejuvenation Res"},{"key":"2025100619514158500_ehaf314-B210","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1001\/archinte.166.22.2502","article-title":"Bone mineral density response to caloric restriction\u2013induced weight loss or exercise-induced weight loss: a randomized controlled trial","volume":"166","author":"Villareal","year":"2006","journal-title":"Arch Intern Med"},{"key":"2025100619514158500_ehaf314-B211","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00125-015-3861-8","article-title":"Associations of total amount and patterns of sedentary behaviour with type 2 diabetes and the metabolic syndrome: the Maastricht study","volume":"59","author":"van der Berg","year":"2016","journal-title":"Diabetologia"},{"key":"2025100619514158500_ehaf314-B212","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fphys.2017.00353","article-title":"Benefits of substituting sitting with standing and walking in free-living conditions for cardiometabolic risk markers, cognition and mood in overweight adults","volume":"8","author":"Duvivier","year":"2017","journal-title":"Front Physiol"},{"key":"2025100619514158500_ehaf314-B213","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2337\/dc15-1240","article-title":"Breaking up prolonged sitting with standing or walking attenuates the postprandial metabolic response in postmenopausal women: a randomized acute study","volume":"39","author":"Henson","year":"2016","journal-title":"Diabetes Care"},{"key":"2025100619514158500_ehaf314-B214","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jsams.2014.03.008","article-title":"Breaking up prolonged sitting with light-intensity walking improves postprandial glycemia, but breaking up sitting with standing does not","volume":"18","author":"Bailey","year":"2015","journal-title":"J Sci Med Sport"},{"key":"2025100619514158500_ehaf314-B215","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMoa1200225","article-title":"Bariatric surgery versus intensive medical therapy in obese patients with diabetes","volume":"366","author":"Schauer","year":"2012","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B216","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJMoa1401329","article-title":"Bariatric surgery versus intensive medical therapy for diabetes\u20143-year outcomes","volume":"370","author":"Schauer","year":"2014","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B217","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes\u20145-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B218","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1007\/s11695-018-3552-x","article-title":"Outcomes of bariatric surgery versus medical management for type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"29","author":"Khorgami","year":"2019","journal-title":"Obes Surg"},{"key":"2025100619514158500_ehaf314-B219","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","article-title":"Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial","volume":"397","author":"Mingrone","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"2025100619514158500_ehaf314-B220","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/S0140-6736(21)00591-2","article-title":"Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants","volume":"397","author":"Syn","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"2025100619514158500_ehaf314-B221","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.117.032130","article-title":"Effects of bariatric surgery in obese patients with hypertension: the GATEWAY randomized trial (gastric bypass to treat obese patients with steady hypertension)","volume":"137","author":"Schiavon","year":"2018","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B222","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"2025100619514158500_ehaf314-B223","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"key":"2025100619514158500_ehaf314-B224","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric\u2013metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"key":"2025100619514158500_ehaf314-B225","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41366-020-00707-z","article-title":"Remission and progression of pre-existing micro- and macroalbuminuria over 15 years after bariatric surgery in Swedish obese subjects study","volume":"45","author":"Shulman","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"2025100619514158500_ehaf314-B226","doi-asserted-by":"publisher","first-page":"e200420","DOI":"10.1001\/jamasurg.2020.0420","article-title":"Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: a randomized clinical trial","volume":"155","author":"Cohen","year":"2020","journal-title":"JAMA Surg"},{"key":"2025100619514158500_ehaf314-B227","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2213-8587(22)00005-5","article-title":"Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study","volume":"10","author":"Raverdy","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025100619514158500_ehaf314-B228","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/eurheartj\/ehac071","article-title":"Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis","volume":"43","author":"van Veldhuisen","year":"2022","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B229","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/MOL.0000000000000889","article-title":"Established and potential cardiovascular risk factors in metabolic syndrome: effect of bariatric surgery","volume":"34","author":"Bashir","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"2025100619514158500_ehaf314-B230","doi-asserted-by":"publisher","first-page":"e175634","DOI":"10.1172\/JCI175634","article-title":"The GLP-1 journey: from discovery science to therapeutic impact","volume":"134","author":"Drucker","year":"2024","journal-title":"J Clin Invest"},{"key":"2025100619514158500_ehaf314-B231","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025100619514158500_ehaf314-B232","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2025100619514158500_ehaf314-B233","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B234","author":"Eli Lilly and Company"},{"key":"2025100619514158500_ehaf314-B235","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"2025100619514158500_ehaf314-B236","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","volume":"402","author":"Aroda","year":"2023","journal-title":"Lancet"},{"key":"2025100619514158500_ehaf314-B237","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B238","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B239","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"2025100619514158500_ehaf314-B240","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B241","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B242","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"2025100619514158500_ehaf314-B243","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B244","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2023","journal-title":"Am Heart J"},{"key":"2025100619514158500_ehaf314-B245","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B246","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B247","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B248","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2025100619514158500_ehaf314-B249","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B250","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B251","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.006","article-title":"Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study","author":"Xiang","year":"2024","journal-title":"J Hepatol"},{"key":"2025100619514158500_ehaf314-B252","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B253","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B254","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"key":"2025100619514158500_ehaf314-B255","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025100619514158500_ehaf314-B256","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"2025100619514158500_ehaf314-B257","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B258","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B259","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B260","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B261","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B262","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B263","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B264","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S2213-8587(24)00362-0","article-title":"Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial","volume":"13","author":"Aggarwal","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025100619514158500_ehaf314-B265","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2025100619514158500_ehaf314-B266","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B267","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B268","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B269","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B270","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B271","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FJC.0000000000001592","article-title":"Metformin-induced proprotein convertase subtilisin\/kexin type 9 inhibition further decreases low-density lipoprotein cholesterol following statin treatment in patients with coronary artery disease and without diabetes","volume":"84","author":"Hu","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025100619514158500_ehaf314-B272","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2213-8587(24)00040-8","article-title":"Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis","volume":"12","author":"Reith","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025100619514158500_ehaf314-B273","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B274","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1161\/CIRCULATIONAHA.123.065520","article-title":"Randomized trial for evaluation in secondary prevention efficacy of combination therapy\u2013statin and eicosapentaenoic acid (RESPECT-EPA)","volume":"150","author":"Miyauchi","year":"2024","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B275","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"2025100619514158500_ehaf314-B276","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-022-01075-x","article-title":"Role of omega-3 fatty acids in cardiovascular disease: the debate continues","volume":"25","author":"Sherratt","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"2025100619514158500_ehaf314-B277","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B278","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/dc16-0126","article-title":"Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes","volume":"39","author":"Digenio","year":"2016","journal-title":"Diabetes Care"},{"key":"2025100619514158500_ehaf314-B279","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2023.05.008","article-title":"Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS)","volume":"375","author":"Jones","year":"2023","journal-title":"Atherosclerosis"},{"key":"2025100619514158500_ehaf314-B280","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B281","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2025100619514158500_ehaf314-B282","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B283","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"},{"key":"2025100619514158500_ehaf314-B284","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B285","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11883-021-00962-z","article-title":"Clinical management of hypertriglyceridemia in the prevention of cardiovascular disease and pancreatitis","volume":"23","author":"Hernandez","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"2025100619514158500_ehaf314-B286","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society task force","volume":"325","author":"Averna","year":"2021","journal-title":"Atherosclerosis"},{"key":"2025100619514158500_ehaf314-B287","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B288","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","article-title":"Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"key":"2025100619514158500_ehaf314-B289","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.2337\/dc24-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2025100619514158500_ehaf314-B290","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B291","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"2025100619514158500_ehaf314-B292","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B293","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B294","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jacc.2023.05.055","article-title":"Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week","volume":"82","author":"Nelson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025100619514158500_ehaf314-B295","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B296","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B297","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B298","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"},{"key":"2025100619514158500_ehaf314-B299","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jjcc.2019.08.002","article-title":"Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome","volume":"75","author":"Yano","year":"2020","journal-title":"J Cardiol"},{"key":"2025100619514158500_ehaf314-B300","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"2025100619514158500_ehaf314-B301","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B302","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"key":"2025100619514158500_ehaf314-B303","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100619514158500_ehaf314-B304","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.jacc.2015.08.035","article-title":"10-Year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (multi-ethnic study of atherosclerosis) with validation in the HNR (Heinz Nixdorf recall) study and the DHS (Dallas heart study)","volume":"66","author":"McClelland","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2025100619514158500_ehaf314-B305","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/CIRCULATIONAHA.117.030645","article-title":"Prevention of \u201cfailure\u201d: is it a failure of prevention?","volume":"137","author":"Nambi","year":"2018","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B306","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.cell.2019.03.028","article-title":"Polygenic prediction of weight and obesity trajectories from birth to adulthood","volume":"177","author":"Khera","year":"2019","journal-title":"Cell"},{"key":"2025100619514158500_ehaf314-B307","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","article-title":"Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations","volume":"50","author":"Khera","year":"2018","journal-title":"Nat Genet"},{"key":"2025100619514158500_ehaf314-B308","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-023-02429-x","article-title":"A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease","volume":"29","author":"Patel","year":"2023","journal-title":"Nat Med"},{"key":"2025100619514158500_ehaf314-B309","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jacl.2017.03.019","article-title":"Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia","volume":"11","author":"Paquette","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2025100619514158500_ehaf314-B310","doi-asserted-by":"publisher","first-page":"e001849","DOI":"10.1161\/CIRCGEN.117.001849","article-title":"Polygenic contribution in individuals with early-onset coronary artery disease","volume":"11","author":"Th\u00e9riault","year":"2018","journal-title":"Circ Genomic Precis Med"},{"key":"2025100619514158500_ehaf314-B311","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1681\/ASN.2020111599","article-title":"Polygenic risk scores for kidney function and their associations with circulating proteome, and incident kidney diseases","volume":"32","author":"Yu","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025100619514158500_ehaf314-B312","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41591-022-01869-1","article-title":"Genome-wide polygenic score to predict chronic kidney disease across ancestries","volume":"28","author":"Khan","year":"2022","journal-title":"Nat Med"},{"key":"2025100619514158500_ehaf314-B313","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.cgh.2021.05.056","article-title":"A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores","volume":"20","author":"De Vincentis","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100619514158500_ehaf314-B314","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1161\/CIRCULATIONAHA.116.024436","article-title":"Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting","volume":"135","author":"Natarajan","year":"2017","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B315","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1161\/CIRCULATIONAHA.118.035658","article-title":"Whole-genome sequencing to characterize monogenic and polygenic contributions in patients hospitalized with early-onset myocardial infarction","volume":"139","author":"Khera","year":"2019","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B316","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jacc.2019.05.043","article-title":"Risk of premature atherosclerotic disease in patients with monogenic versus polygenic familial hypercholesterolemia","volume":"74","author":"Trinder","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025100619514158500_ehaf314-B317","doi-asserted-by":"publisher","first-page":"e003106","DOI":"10.1161\/CIRCGEN.120.003106","article-title":"Polygenic risk score for low-density lipoprotein cholesterol is associated with risk of ischemic heart disease and enriches for individuals with familial hypercholesterolemia","volume":"14","author":"Wu","year":"2021","journal-title":"Circ Genomic Precis Med"},{"key":"2025100619514158500_ehaf314-B318","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/S0140-6736(14)61730-X","article-title":"Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials","volume":"385","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"2025100619514158500_ehaf314-B319","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.119.044434","article-title":"Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial","volume":"141","author":"Damask","year":"2020","journal-title":"Circulation"},{"key":"2025100619514158500_ehaf314-B320","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2337\/db20-0530","article-title":"A polygenic score for type 2 diabetes risk is associated with both the acute and sustained response to sulfonylureas","volume":"70","author":"Li","year":"2021","journal-title":"Diabetes"},{"key":"2025100619514158500_ehaf314-B321","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","article-title":"Clinical use of current polygenic risk scores may exacerbate health disparities","volume":"51","author":"Martin","year":"2019","journal-title":"Nat Genet"},{"key":"2025100619514158500_ehaf314-B322","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41591-023-02260-4","article-title":"Cardiometabolic health, diet and the gut microbiome: a meta-omics perspective","volume":"29","author":"Valles-Colomer","year":"2023","journal-title":"Nat Med"},{"key":"2025100619514158500_ehaf314-B323","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41579-019-0256-8","article-title":"Diet-microbiota interactions and personalized nutrition","volume":"17","author":"Kolodziejczyk","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"2025100619514158500_ehaf314-B324","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.cell.2015.11.001","article-title":"Personalized nutrition by prediction of glycemic responses","volume":"163","author":"Zeevi","year":"2015","journal-title":"Cell"},{"key":"2025100619514158500_ehaf314-B325","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1038\/s41467-023-41042-x","article-title":"Impact of dietary interventions on pre-diabetic oral and gut microbiome, metabolites and cytokines","volume":"14","author":"Shoer","year":"2023","journal-title":"Nat Commun"},{"key":"2025100619514158500_ehaf314-B326","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature12198","article-title":"Gut metagenome in European women with normal, impaired and diabetic glucose control","volume":"498","author":"Karlsson","year":"2013","journal-title":"Nature"},{"key":"2025100619514158500_ehaf314-B327","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature11450","article-title":"A metagenome-wide association study of gut microbiota in type 2 diabetes","volume":"490","author":"Qin","year":"2012","journal-title":"Nature"},{"key":"2025100619514158500_ehaf314-B328","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","article-title":"Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study","volume":"25","author":"Depommier","year":"2019","journal-title":"Nat Med"},{"key":"2025100619514158500_ehaf314-B329","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fuad039","article-title":"Faecalibacterium: a bacterial genus with promising human health applications","volume":"47","author":"Mart\u00edn","year":"2023","journal-title":"FEMS Microbiol Rev"},{"key":"2025100619514158500_ehaf314-B330","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/s41591-024-02951-6","article-title":"Effects of a personalized nutrition program on cardiometabolic health: a randomized controlled trial","volume":"30","author":"Bermingham","year":"2024","journal-title":"Nat Med"},{"key":"2025100619514158500_ehaf314-B331","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41591-021-01399-2","article-title":"Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial","volume":"27","author":"Mocanu","year":"2021","journal-title":"Nat Med"},{"key":"2025100619514158500_ehaf314-B332","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"2025100619514158500_ehaf314-B333","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL)","year":"2016","journal-title":"J Hepatol"},{"key":"2025100619514158500_ehaf314-B334","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"2025100619514158500_ehaf314-B335"},{"key":"2025100619514158500_ehaf314-B336","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1097\/HEP.0000000000000647","article-title":"AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis","volume":"79","author":"Kaplan","year":"2024","journal-title":"Hepatology"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/38\/3685\/63062033\/ehaf314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/38\/3685\/63062033\/ehaf314.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:51:52Z","timestamp":1759794712000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/38\/3685\/8125503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":336,"journal-issue":{"issue":"38","published-online":{"date-parts":[[2025,5,7]]},"published-print":{"date-parts":[[2025,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf314","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,7]]},"published":{"date-parts":[[2025,5,7]]}}}